- Home
- DX vs DNTH Comparison
DX vs DNTH Comparison
Compare DX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- DNTH
- Stock Information
- Founded
- DX 1987
- DNTH 2015
- Country
- DX United States
- DNTH United States
- Employees
- DX N/A
- DNTH N/A
- Industry
- DX Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- DX Real Estate
- DNTH Health Care
- Exchange
- DX Nasdaq
- DNTH Nasdaq
- Market Cap
- DX 1.7B
- DNTH 1.4B
- IPO Year
- DX N/A
- DNTH N/A
- Fundamental
- Price
- DX $13.44
- DNTH $33.73
- Analyst Decision
- DX Buy
- DNTH Strong Buy
- Analyst Count
- DX 4
- DNTH 11
- Target Price
- DX $13.33
- DNTH $65.22
- AVG Volume (30 Days)
- DX 4.7M
- DNTH 503.3K
- Earning Date
- DX 10-20-2025
- DNTH 11-05-2025
- Dividend Yield
- DX 15.18%
- DNTH N/A
- EPS Growth
- DX 35.65
- DNTH N/A
- EPS
- DX 1.66
- DNTH N/A
- Revenue
- DX $230,447,000.00
- DNTH $4,854,000.00
- Revenue This Year
- DX N/A
- DNTH N/A
- Revenue Next Year
- DX $134.14
- DNTH N/A
- P/E Ratio
- DX $8.10
- DNTH N/A
- Revenue Growth
- DX 87.09
- DNTH 17.87
- 52 Week Low
- DX $10.79
- DNTH $13.37
- 52 Week High
- DX $14.52
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- DX 60.46
- DNTH 47.36
- Support Level
- DX $13.04
- DNTH $32.28
- Resistance Level
- DX $13.66
- DNTH $35.40
- Average True Range (ATR)
- DX 0.24
- DNTH 1.62
- MACD
- DX -0.02
- DNTH -0.20
- Stochastic Oscillator
- DX 66.67
- DNTH 27.78
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.